Browse this directory of active clinical trials at The University of Tennessee Medical Center. If you are interested in any of these trials, contact us at 865-305-4893.
BBI-DSP7888-201G— A Phase 2 randomized trial of DSP-7888 dosing emulsion in combination with Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma following initial therapy.
NRG-BR003 - A randomized, phase 3 trial for node-positive, high-risk node-negative triple-negative invasive breast cancer.
Alliance A011502—A randomized, phase III double-blind, placebo-controlled trial of Aspirin as adjuvant therapy for HER2 Negative Breast Cancer. The ABC trial.
Alliance A011202—A randomized, Phase III trial comparing axillary lymph node dissection to axillary radiation in Breast Cancer patients (cT1-3 N1) who have positive sentinel lymph node dissection after neoadjuvant chemotherapy.
SWOG S0820 - A randomized, placebo controlled trial of Eflornithine and Sulindac to prevent recurrence of high risk adenomas and primary colorectal cancers in patients with Stage 0-Stage III colon or rectal cancer.
Genital and Urinary Cancer
Astra Zeneca D4191C00068 Strong - An open-label, multi-centre, safety study of fixed-dose Durvalumab + Tremelimumab combination therapy or Durvalumab monotherapy in advanced solid malignancies. Current module open is for Bladder Cancer.
Eisai E7080-G000-218 - A Randomized, double-blind, Phase 2 trial to assess safety and efficacy of Lenvatinib at two different starting doses (18 mg vs. 14 mg QD) in combination with Everolimus (5 mg QD) in Renal Cell Carcinoma following one prior VEGF-targeted treatment.
GOG-0238 - A randomized, phase 2 trial of pelvic irradiation with or without concurrent weekly Cisplatin in patients with recurrent endometrial cancer.
Tesaro First—A Phase 3 comparison of platinum-based therapy with TSR-042 and Niraparib versus standard of care platinum-based therapy as first line treatment of Stage III or IV nonmucinous epithelial ovarian cancer.
Head and Neck Cancer
RTOG 1008—A randomized, Phase 2/ Phase 3 study of adjuvant, concurrent radiation and chemotherapy versus radiation alone in resected high-risk malignant salivary gland tumors.
Galera GTI-4419-301—A Phase 3, randomized, double-blind, placebo-controlled, multi-center study of the Superoxide Dismutase Mimetic GC4419 to reduce Severe Oral Mucositis (SOM) associated with Chemoradiotherapy for Locally advanced, non-metastatic Head and Neck cancer.
Sillajen Jx594-HEP024 - A randomized, phase 3 open-label study comparing Pexa-Vec followed by Sorafenib vs. Sorafenib alone in patients with advanced hepatocellular carcinoma without prior systemic therapy.
Connect MDS/AML - The myelodysplastic syndromes and acute myeloid leukemia disease registry.
Helsinn Pran-16-52-AML - A Phase III, double-blind, placebo-controlled, multicenter, randomized study of Pracinostat in combination with Azacitidine in patients ≥18 years with newly diagnosed Acute Myeloid Leukemia unfit for standard Induction Chemotherapy.
Non-Small Cell Lung Cancer
BrightPath GRN-1201—A pilot, Open-label, multi-center, multi-dose study of GRN-1201 added to Pembrolizumab in subjects with PD-L1+ Non-Small Cell Lung Cancer.
Astra Zeneca Pacific-6—A Phase II, open-label, multi-center, international safety study of Durvalumab following Sequential Chemotherapy and Radiation Therapy in patients with Stage III, Unresectable Non-Small Cell Lung Cancer.
Small Cell Lung Cancer
No studies at this time.
BMS CA209-812 Hodgkin’s Lymphoma - A randomized, open-label, Phase 3 trial of Nivolumab plus Brentuximab Vedotin versus Brentuximab Vedotin alone in participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 812)
Amgen Herpetic Infection 20130193—A post-marketing prospective cohort study of Melanoma patients treated with Imlygic (Talimogene Laherparepvec) in clinical practice to characterize the risk of Herpetic infection among patients, close contacts, and health care providers, and long-term safety in treated patients.
Merck MK-3475-716—A Randomized, double-blind, Phase 3 study of Adjuvant Therapy with Pembrolizumab versus placebo in resected high risk Stage II Melanoma (Keynote 716).
BMS Preamble-CA204008 ST - An observational evaluation in Multiple Myeloma.
No studies at this time.
Lilly 13Y-MC-JPCM—A Phase 2, randomized, double-blind, placebo-controlled study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in patients with Metastatic Castration-resistant prostate cancer.
Regeneron Case—A prospective survivorship cohort study of adult patients with cutaneous squamous cell carcinoma undergoing treatment with Cemiplimab.
Acadia ACP-103-045—A double-blind, placebo controlled, relapse prevention study of Pimavanserin for the treatment of hallucinations and delusions associated with Dementia-related psychosis.
Biogen 109MS401 ESTEEM - A multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera™ (Dimethyl Fumarate) when used in routine medical practice in the treatment of Multiple Sclerosis (ESTEEM).
Vanderbilt University Medical Center FEAT—A randomized, controlled trail of Eighteen (0.014-0.0155) platinum coils versus standard (<0.014) platinum coils in the endovascular treatment of medium-sized (6-14 mm) intracranial aneurysms.
Bayer 1454032/18894 POET Essure - An open-label, non-randomized, prospective observational cohort study to assess post procedural outcomes in two cohorts of women who Chose to undergo either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization.
Medicines 360 M360-L105—A Phase 3, multi-center, open-label study of a Levonorgestrel 52 mg Intrauterine system for the treatment of Heavy Menstrual bleeding.
ObsEva 16-OBE2109-008 Primrose—A Phase 3, multi-center, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
GE-265-303 A Phase 3, Open-label, study of Flupiridaz (18F) injection for Positron Emission Tomography (PET) imaging for assessment of myocardial perfusion in patients referred for invasive coronary angiography because of suspected coronary artery disease.
Duke University CONNECT-HF—Care Optimization through Patient and Hospital Engagement Clinical Trial for Heart Failure. A clinical trial of Quality Improvement Initiatives.
Humacyte CLN-PRO-V007—A Phase 3 study to compare the efficacy and safety of Humacyte’s Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease.
No studies at this time.